Business Wire

Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

Share

Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.

“We are encouraged by the European Commission’s and European Medicines Agency’s recognition of the benefit that zanidatamab can provide in the treatment of HER2-expressing gastric cancers as we continue to expand our clinical development globally,” said Diana Hausman, M.D., Chief Medical Officer at Zymeworks.

The EC grants Orphan Drug designation to therapies that represent a significant benefit over existing treatments, are intended for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease, and where prevalence of the condition in the European Union (EU) is less than 5 in 10,000 persons. Orphan drug designation gives companies certain benefits, including 10 years of market exclusivity following regulatory approval, reduced regulatory fees, clinical protocol assistance, and access to research grants.

“While gastric cancer is a rare disease, European countries experience the highest incidence rates among all Western countries,” said James Priour, Senior Vice President, Commercial, at Zymeworks. “The European Commission’s granting of Orphan Drug designation for zanidatamab represents an important step towards bringing this promising investigational medicine to patients in Europe and around the world.”

Zymeworks previously received Orphan Drug designations for zanidatamab in gastric, biliary tract and ovarian cancers from the US FDA, as well as two Fast Track designations from the FDA for zanidatamab.

About Zanidatamab

Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding, and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and registration-enabling clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The US FDA has granted two Fast Track designations to zanidatamab, one as a single agent for refractory BTC and one in combination with standard of care chemotherapy, for first-line Gastroesophageal Adenocarcinoma (GEA). Zanidatamab has also received Orphan Drug designations for the treatment of biliary tract, gastric and ovarian cancers from the US FDA, in addition to Orphan Drug designation for the treatment of gastric cancer from the European Medicines Agency.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements that relate to the anticipated benefits of orphan drug designation, the potential therapeutic benefit that zanidatamab can provide, Zymeworks’ clinical and preclinical development of its product candidates, and other information that is not historical information. When used herein, words such as “plan”, “expect”, “may”, “can”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contact information

Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com

Tiffany Tolmie
(604) 678-1388
ir@zymeworks.com

Media Inquiries:
Mary Klem
(604) 678-1388
media@zymeworks.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Closes H.I.G. Europe Capital Partners III at €1.1 Billion24.11.2020 10:00:00 CETPress release

H.I.G. Capital (“H.I.G.”), a leading global alternative asset management firm with $42 billion of equity capital under management, is pleased to announce the closing of its third European Lower Middle Market Fund, H.I.G. Europe Capital Partners III (the “Fund”). The Fund closed with aggregate capital commitments of €1.1 billion, exceeding its target. The Fund will continue the successful strategy of its two predecessor funds, by making private equity investments in lower middle market companies, primarily in Western Europe. Sami Mnaymneh and Tony Tamer, H.I.G. Co-Founders and Co-CEOs, commented: “We are delighted with the continued support from our limited partner base, which reflects their confidence in the capability of our European team and our differentiated investment approach.” Wolfgang Biedermann, Head of H.I.G. Europe Buyouts, added: “The team is excited to build upon H.I.G.’s successful European lower middle market strategy. The current economic environment in Europe leaves us

FERI Group and Target Global Join Forces for New Growth Fund24.11.2020 09:00:00 CETPress release

The Bad Homburg-based FERI Group is cooperating with Target Global in the management and placement of a new growth fund. The two companies will work together in the selection of target investments and the placement of this new alternative investment fund for growth capital. This cooperation between one of the leading investment houses in the German-speaking region and one of the most active European venture capital investment companies is the first of its kind. The new Target Global Growth Fund offers investment opportunities in selected growth companies to semi-professional and professional investors. The fund will invest in start-ups with strong growth potential that offer digital products and services in typical European industries for large and preferably global markets – mainly market platforms, Fintechs and service software providers. The fund's investment focus is on companies in early and mid growth phases with valuations in excess of EUR 50 million. "The fund opens up new inve

Exclusive Networks Acquires Nuaware to Accelerate Cloud and DevOps Opportunities for Channel and Vendor Partners24.11.2020 09:00:00 CETPress release

Exclusive Networks today announced the acquisition of Nuaware, a hyper growth, born-in-the-cloud distributor at the bleeding edge of cloud, DevSecOps and containerisation. The move adds immediate global scale and services capability to the Nuaware proposition and portfolio, while enabling Exclusive Networks, its vendors and partner community with a unique skill set for capitalising on immense demand shifts brought about by digital transformation. Jesper Trolle, CEO at Exclusive Networks said: "DevOps tool chains, containers and the emergence of DevSecOps are specialist areas where Nuaware has carved a truly unique niche in distribution. This acquisition puts us where we want to be in this space, giving our partners a readymade on-ramp into new high-growth opportunities. Large vendors being drawn to these markets are seeking turnkey channel solutions, and their established partner ecosystems have technical skills gaps that demand credible support. We can now meet these kinds of challeng

Aker BP and Cognite Pioneer Robotics Deployment Offshore to Transform Oil and Gas Industry with Autonomous Mission24.11.2020 09:00:00 CETPress release

Cognitea global industrial AI software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world, has partnered with fully-fledged exploration and production company Aker BP to deploy Spot, the quadruped robotic dog, to pioneer the remote controlled offshore mission on the Skarv installation, 210 kilometers offshore in the North Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005292/en/ Cognite Data Fusion powers Spot, the Boston Dynamics quadruped robot dog, as it completes autonomous mission onboard Aker BP Skarv installation in the North Sea (Photo: Business Wire) The effort continues to build upon Aker BP and Cognite’s bold digital agenda to transform the industry through digitalization, which will result in improved efficiency, safety, and sustainability offshore. This recent endeavor signals a significant opportunity to transform the oil and gas in

beCloud Selects P.I. Works to Drive Automation of its Nationwide Multi-Operator and Multi-Vendor LTE Network24.11.2020 06:00:00 CETPress release

beCloud, Belarus’ telecommunications infrastructure and service provider, has selected P.I. Works’ cutting-edge network management solutions to drive the automation and proactive monitoring of its multi-operator and multi-vendor 4G network. The deployment has been initiated and will oversee the installation of P.I. Works’ next-generation automation and analytics products, EXA and VantagePM, to enable AI-powered network automation for 24/7 optimization across the operator’s networks. EXA, which runs on the P.I. Works EVO Platform™, will empower beCloud to automatically manage its traffic load, identify cross connection problems without visiting the sites and maximize 4G coverage using existing resources. VantagePM, on the other hand, will enable beCloud to gauge insights into different operator users, monitor individual operator service quality levels, perform rigorous anomaly detection and implement easy-to-use interactive dashboards. To deliver this, P.I. Works utilizes PLMN (network

Global Superstars BTS Team Up With Iconic MapleStory Games in Brand New Collaboration24.11.2020 04:00:00 CETPress release

Nexon America Inc.: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123006306/en/ MS x BTS Collab Logo (Graphic: Business Wire) WHAT: Today, Nexon announced a collaboration with global record-breaking pop superstars, BTS with the iconic MMORPG IP, MapleStory coming soon. Leading up to the in-game collaboration inMapleStory and MapleStory M, players will be treated to three behind the scenes videos surrounding the MapleStory X BTS collaboration with one new video releasing each week beginning on November 25 via MapleStory’s YouTube channel at youtube.com/MapleStory. The video content will feature BTS sharing their journey growing up with MapleStory through childhood and their fondness for the game. More details on the collaboration will be announced. To stay up to date on the MapleStory X BTS collaboration, visit maplestory.com/maplestoryxbts and follow @maplestory and @playmaplem on Twitter. WHO: MapleStory & MapleStory M

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom